Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pulmonx (LUNG) EBIT Margin (2019 - 2025)

Historic EBIT Margin for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to 66.94%.

  • Pulmonx's EBIT Margin rose 23700.0% to 66.94% in Q3 2025 from the same period last year, while for Sep 2025 it was 62.38%, marking a year-over-year increase of 110200.0%. This contributed to the annual value of 68.87% for FY2024, which is 213200.0% up from last year.
  • Per Pulmonx's latest filing, its EBIT Margin stood at 66.94% for Q3 2025, which was up 23700.0% from 62.05% recorded in Q2 2025.
  • Pulmonx's EBIT Margin's 5-year high stood at 56.46% during Q4 2024, with a 5-year trough of 145.28% in Q1 2022.
  • Its 5-year average for EBIT Margin is 88.82%, with a median of 85.9% in 2023.
  • The largest annual percentage gain for Pulmonx's EBIT Margin in the last 5 years was 2098800bps (2021), contrasted with its biggest fall of -643300bps (2021).
  • Pulmonx's EBIT Margin (Quarter) stood at 90.21% in 2021, then decreased by -5bps to 94.83% in 2022, then grew by 24bps to 72.2% in 2023, then rose by 22bps to 56.46% in 2024, then fell by -19bps to 66.94% in 2025.
  • Its last three reported values are 66.94% in Q3 2025, 62.05% for Q2 2025, and 64.62% during Q1 2025.